Download PDF
Z Gastroenterol 2020; 58(08): 773-777
DOI: 10.1055/a-1190-5681
Kasuistik

Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure

Ansprechen eines fortgeschrittenen HCC auf Pembrolizumab und Lenvatinib Kombinationstherapie trotz Versagen der Monotherapie
Nadine Schulte‡
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Moying Li‡
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Tianzuo Zhan
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Lena Dreikhausen
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Janina Sollors
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Christoph Antoni
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Steffen Diehl
2   Department of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Stefan O. Schoenberg
2   Department of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Nuh Rahbari
3   Department of Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Christoph Reissfelder
3   Department of Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Frank A. Giordano
4   Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany
,
Matthias P. Ebert
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Andreas Teufel
1   Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed to show statistically significant improvement.

Recently, the combination of atezolizumab and bevacizumab demonstrated efficacy of combining ICI and VEGF inhibition, further substantiating previous data on synergistic mechanisms among respective substance classes.

As TKI treatment is currently standard of care for aHCC, and ICIs are approved by the FDA and available in many areas of the world, numerous patients may have been treated with monotherapy of those drugs. However, it remains unclear if failure to monotherapy has an impact on combination therapy. We therefore report a patient well responding to combination therapy despite previous failures to TKI and ICI monotherapy.

Zusammenfassung

In den letzten Jahren wurden Immuncheckpointinhibitoren (ICIs) erfolgreich in die Krebstherapie eingeführt. Für einige Tumorentitäten sind diese Substanzen bereits unverzichtbarer Bestandteil der therapeutischen Optionen geworden. Beim fortgeschrittenen hepatozellulären Karzinom (aHCC) zeigte sich hingegen für die Monotherapie bisher keine statistisch signifikante Verbesserung des Patientenüberlebens.

Kürzlich wurde jedoch für die Kombination von Atezolizumab und Bevacizumab eine sehr gute Wirksamkeit gezeigt. Die Wirksamkeit einer Kombination von ICI- und VEGF-Hemmung, aber auch frühe Daten zu synergistischen Mechanismen der Substanzklassen wurden so weiter untermauert.

Da die TKI-Behandlung derzeit der Standard der aHCC-Behandlung ist und ICIs von der FDA zugelassen und in vielen anderen Regionen der Welt erhältlich sind, wurden trotz fehlender Zulassung in Europa zahlreiche Patienten mit einer Monotherapie dieser Medikamente behandelt. Es ist jedoch unklar, ob ein Nichtansprechen auf diese Substanzen in der Monotherapie Bedeutung für die Kombination hat. Wir berichten über eine erste Patientin, die trotz vorausgegangenen Nichtansprechens auf TKI- und ICI-Monotherapie sehr gut auf die Kombinationstherapie angesprochen hat.

Key words

PD-1 - tyrosine kinase inhibitor - lenvatinib - pembrolizumab - atezolizumab - bevacizumab - nivolumab - immunotherapy - liver cancer - HCC

Schlüsselwörter

PD-1 - tyrosine kinase inhibitor - TKI - Lenvatinib - Pembrolizumab - Aatezolizumab - Bevacizumab - Nivolumab - Immuntherapie - Leberzellkarzinom - HCC


Publication History

Received: 27 January 2020

Accepted: 23 May 2020

Article published online:
12 August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173
    CrossrefPubMedGoogle Scholar
  • 2 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66
    CrossrefPubMedGoogle Scholar
  • 3 Kudo M. Cabozantinib for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019; 8: 153-156
    CrossrefPubMedGoogle Scholar
  • 4 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
    CrossrefPubMedGoogle Scholar
  • 5 Wege H, Li J, Ittrich H. Treatment lines in hepatocellular carcinoma. Visc Med 2019; 35: 266-272
    CrossrefPubMedGoogle Scholar
  • 6 Finn RS, Ryoo BY, Merle P. et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clinical Oncol 2019; 37: 4004
    CrossrefPubMedGoogle Scholar
  • 7 BMS PR. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibbs-opdivo-nivolumab-receives-fda-approval-t
    PubMedGoogle Scholar
  • 8 Roche PR. https://www.roche.com/media/releases/med-cor-2019-10-21.htm
    PubMedGoogle Scholar
  • 9 Llovet J, Finn RS, Ikeda M. et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results. Ann Oncol 2019; 30: v253-v324
    CrossrefPubMedGoogle Scholar
  • 10 Alfarouk KO, Stock CM, Taylor S. et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 2015; 15: 71
    CrossrefPubMedGoogle Scholar
  • 11 Siravegna G, Mussolin B, Buscarino M. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 795-801
    CrossrefPubMedGoogle Scholar
  • 12 Xu MJ, Feng M. Radiation therapy in HCC: what data exist and what data do we need to incorporate into guidelines?. Semin Liver Dis 2019; 39: 43-52
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
    CrossrefPubMedGoogle Scholar
  • 14 Gallicchio R, Nardelli A, Mainenti P. et al. Therapeutic strategies in HCC: radiation modalities. Biomed Res Int 2016; 2016: 1295329
    CrossrefPubMedGoogle Scholar
  • 15 Byun HK, Kim HJ, Im YR. et al. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlenther Onkol 2019; 196: 132-141
    CrossrefPubMedGoogle Scholar
  • 16 Ngwa W, Irabor OC, Schoenfeld JD. et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018; 18: 313-322
    CrossrefPubMedGoogle Scholar
  • 17 Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2018; 52: 117-124
    CrossrefPubMedGoogle Scholar
  • 18 Becht E, de Reynies A, Giraldo NA. et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res 2016; 22: 4057-4066
    CrossrefPubMedGoogle Scholar
  • 19 Gabrilovich DI, Chen HL, Girgis KR. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103
    CrossrefPubMedGoogle Scholar
  • 20 Gabrilovich D, Ishida T, Oyama T. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-4166
    CrossrefPubMedGoogle Scholar
  • 21 Oyama T, Ran S, Ishida T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-1232
    CrossrefPubMedGoogle Scholar
  • 22 Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174
    CrossrefPubMedGoogle Scholar
  • 23 Huang Y, Yuan J, Righi E. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109: 17561-17566
    CrossrefPubMedGoogle Scholar
  • 24 Kloepper J, Riedemann L, Amoozgar Z. et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 2016; 113: 4476-4481
    CrossrefPubMedGoogle Scholar
  • 25 Peterson TE, Kirkpatrick ND, Huang Y. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 2016; 113: 4470-4475
    CrossrefPubMedGoogle Scholar
  • 26 Schmittnaegel M, Rigamonti N, Kadioglu E. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med 2017; 9: eaak9670
    CrossrefPubMedGoogle Scholar
  • 27 Matsui J, Yamamoto Y, Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-671
    CrossrefPubMedGoogle Scholar
  • 28 Okamoto K, Kodama K, Takase K. et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013; 340: 97-103
    CrossrefPubMedGoogle Scholar
  • 29 Makker V, Rasco D, Vogelzang NJ. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019; 20: 711-718
    CrossrefPubMedGoogle Scholar
  • 30 Taylor MH, Lee CH, Makker V. et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020; 38: 1154-1163
    CrossrefPubMedGoogle Scholar